AFP and hepatocellular carcinoma: A recent study suggests that GALAD is more sensitive and specific than AFP in detecting preclinical HCC, and use of GALAD may prevent unnecessary MRI or CT (computerized tomography) tests in up to 54% of patients with cirrhosis (54).